The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including:

At high concentrations, mAb-X became too viscous (thick and syrupy). This would make it difficult to inject through a thin needle.

The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable.